🔎 Trials Near Me

Home › B-Cell Leukemia › Washington

B-Cell Leukemia clinical trials in Washington, DC

5 studies for B-Cell Leukemia are looking for participants at sites in and around Washington (within about 30 miles). Open a study to see who can join and how to contact the study team.

Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →

CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies

RecruitingPhase 1/2
  • National Institutes of Health Clinical Center, Bethesda · 7 mi away
Ages 3 to 39 · All sexes · Updated Sep 30, 2026 · NCT05442515

Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)

RecruitingObservational study
  • National Institutes of Health Clinical Center, Bethesda · 7 mi away
Ages 18 to 110 · All sexes · Updated Sep 28, 2026 · NCT00923507

Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)

RecruitingPhase 3
  • Research Site, Bethesda · 7 mi away
Ages 18 to 18 · All sexes · Updated Sep 8, 2026 · NCT07509151

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

RecruitingPhase 3
  • American Oncology Partners of Maryland, PA, Bethesda · 7 mi away
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT05254743

ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL

RecruitingPhase 3
  • The Center for Cancer and Blood Disorders-Bethesda, Bethesda · 7 mi away
Ages 18 and older · All sexes · Updated Aug 11, 2026 · NCT07342478

B-Cell Leukemia trials in other cities

Other studies in Washington

From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.